Patient | Age (years) | Disease subtype | Number of prior lines of therapy | Baseline bone marrow blasts | IPSS-R risk | Mutations | Best response | Duration of response (months) |
---|---|---|---|---|---|---|---|---|
#1 | 59 | MDS | 1 | 15% | Very high | TP53, BRINP3 | Not evaluable | N/A |
#2 | 71 | MDS | 2 | 4% | High | ASXL1, NF1, RUNX1, SF3B1, PHF6 | Stable disease | 5.1 |
#3 | 83 | CMML | 1 | 6% | Intermediate | SF3B1, SRSF2, ASXL1, RUNX1, SETBP1, PRPF40B | mCR | 4.4 |
#4 | 74 | MDS | 1 | 3% | Very high | TP53 | CR | 14.8 (ongoing) |
#5 | 49 | CMML | 2 | 11% | Very high | ASXL1, PTPN11, U2AF1 | mCR | 2.8 |
#6 | 72 | MDS | 1 | 2% | High | EZH2, SF3B1, TET2, RAD21 | HI-P | 10.9 |
#7 | 76 | MDS | 1 | 9% | High | TP53, ASXL2, ETV6, SETBP1, ZRSR2 | mCR + HI-E + HI-N | 8.0 |
#8 | 78 | MDS | 3 | 14% | Very high | IDH2, SRSF2, FLT3-D835, RUNX1 | mCR + HI-N | 3.9 |